LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Other EventsItem 8.01OTHER EVENTS.
On December 21, 2017, La Jolla Pharmaceutical Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) approved GiaprezaTM (angiotensin II) to increase blood pressure in adults with septic or other distributive shock.
Item 8.01FINANCIAL STATEMENTS AND EXHIBITS.
(d)Exhibits. The following exhibits are furnished with this report on Form 8-K:
|
Exhibit No. |
Description |
|
Press Release dated December 21, 2017
|
LA JOLLA PHARMACEUTICAL CO ExhibitEX-99.1 2 exhibit12212017.htm EXHIBIT 99.1 Exhibit La Jolla Pharmaceutical Company Announces FDA Approval of GiaprezaTM (angiotensin II)Giapreza increases blood pressure in adults with septic or other distributive shockLa Jolla to host conference call and webcast at 8:30 a.m. EST on December 22,…To view the full exhibit click here
About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
